William Blair Estimates Amgen’s Q4 Earnings (NASDAQ:AMGN)

Amgen Inc. (NASDAQ:AMGN) – Equities research analysts at William Blair dropped their Q4 2024 EPS estimates for shares of Amgen in a note issued to investors on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the medical research company will post earnings of $5.05 per share for the quarter, down from their previous estimate of $5.12. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.57 per share. William Blair also issued estimates for Amgen’s FY2025 earnings at $21.34 EPS.

AMGN has been the subject of a number of other reports. Redburn Partners lowered their price objective on shares of Amgen from $200.00 to $195.00 in a research report on Wednesday, November 27th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research note on Tuesday, October 22nd. Truist Financial reduced their price objective on Amgen from $333.00 to $298.00 and set a “hold” rating on the stock in a research report on Wednesday, January 8th. Piper Sandler dropped their target price on Amgen from $344.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, January 2nd. Finally, StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $314.91.

Amgen Stock Up 1.0 %

Shares of NASDAQ AMGN opened at $274.81 on Wednesday. The stock has a 50-day moving average price of $272.95 and a two-hundred day moving average price of $306.92. Amgen has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The company has a market cap of $147.72 billion, a price-to-earnings ratio of 35.19, a PEG ratio of 2.78 and a beta of 0.56.

Amgen (NASDAQ:AMGN) last issued its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to the consensus estimate of $8.50 billion. During the same quarter last year, the business posted $4.96 EPS. The company’s revenue was up 23.2% compared to the same quarter last year.

Hedge Funds Weigh In On Amgen

A number of large investors have recently modified their holdings of AMGN. Stablepoint Partners LLC boosted its stake in Amgen by 0.6% during the 4th quarter. Stablepoint Partners LLC now owns 22,469 shares of the medical research company’s stock valued at $5,856,000 after purchasing an additional 135 shares during the last quarter. Regatta Capital Group LLC boosted its position in shares of Amgen by 1.1% during the fourth quarter. Regatta Capital Group LLC now owns 6,147 shares of the medical research company’s stock valued at $1,602,000 after buying an additional 64 shares during the last quarter. KFG Wealth Management LLC grew its holdings in Amgen by 1.5% during the fourth quarter. KFG Wealth Management LLC now owns 3,249 shares of the medical research company’s stock worth $847,000 after buying an additional 49 shares in the last quarter. Jamison Private Wealth Management Inc. raised its position in Amgen by 4.1% in the 4th quarter. Jamison Private Wealth Management Inc. now owns 25,564 shares of the medical research company’s stock valued at $6,663,000 after buying an additional 997 shares during the last quarter. Finally, Blue Square Asset Management LLC lifted its stake in Amgen by 104.0% during the 4th quarter. Blue Square Asset Management LLC now owns 14,271 shares of the medical research company’s stock valued at $3,720,000 after acquiring an additional 7,277 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be paid a $2.38 dividend. The ex-dividend date is Friday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a dividend yield of 3.46%. Amgen’s dividend payout ratio (DPR) is currently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.